ArticleMalaria journal2013
The burden of Plasmodium vivax relapses in an Amerindian village in French Guiana.
Article in Malaria journal, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 26 citations in OpenAlex.
- Randomized trial of primaquine hypnozoitocidal efficacy when administered with artemisinin-combined blood schizontocides for radical cure of Plasmodium vivax in Indonesia.BMC medicine · 2015Trial
- [Malaria control in French Guiana: What are the challenges in this last endemic French territory in 2024?]Medecine tropicale et sante internationale · 2025Article
- Which diagnostic test to use for Testing and Treatment strategies inLancet regional health. Americas · 2024Article
- Kinetics of glucose-6-phosphate dehydrogenase (G6PD) activity during Plasmodium vivax infection: implications for early radical malaria treatment.Malaria journal · 2024Article
- Determination of different social groups' level of knowledge about malaria in a multicultural Amazonian cross-border context.BMC public health · 2023Article
- Resurgence risk for malaria, and the characterization of a recent outbreak in an Amazonian border area between French Guiana and Brazil.BMC infectious diseases · 2020Article
- Complex malaria epidemiology in an international border area between Brazil and French Guiana: challenges for elimination.Tropical medicine and health · 2019Article
- Primaquine 30 mg/day versus 15 mg/day during 14 days for the prevention of Plasmodium vivax relapses in adults in French Guiana: a historical comparison.Malaria journal · 2018Article
- Characterization ofFrontiers in microbiology · 2018Article
- Management of relapsing Plasmodium vivax malaria.Expert review of anti-infective therapy · 2016Review
- EVALUATION OF CIRCUMSPOROZOITE PROTEIN OF Plasmodium vivax TO ESTIMATE ITS PREVALENCE IN OIAPOQUE , AMAPÁ STATE, BRAZIL, BORDERING FRENCH GUIANA.Revista do Instituto de Medicina Tropical de Sao Paulo · 2016Article
- Sub-Saharan red cell antigen phenotypes and glucose-6-phosphate dehydrogenase deficiency variants in French Guiana.Malaria journal · 2016Article
- Primaquine treatment and relapse in Plasmodium vivax malaria.Pathogens and global health · 2016Review
- Frequency and distribution of mixed Plasmodium falciparum-vivax infections in French Guiana between 2000 and 2008.Malaria journal · 2015Article
- Uncovering the transmission dynamics of Plasmodium vivax using population genetics.Pathogens and global health · 2015Review
- Malaria on the Guiana Shield: a review of the situation in French Guiana.Memorias do Instituto Oswaldo Cruz · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Malaria is a public health problem in French Guiana. Plasmodium vivax is the most frequent parasite. The objective of this analysis was to estimate the proportion of relapses in the burden of vivax malaria using the statistical rule stating that any case of vivax malaria occurring less than 90 days following a first episode is a relapse.A total of 622 subjects were followed for 2,9 years with 336 first single episodes of P. vivax malaria, and a total of 1,226 episodes of vivax malaria among which 559 were relapses (45.5%). For 194 patients having had falciparum malaria followed by vivax malaria it was estimated that 19% of the vivax episodes occurred less than 90 days following the falciparum episode and thus were possibly relapses due to the activation of latent hypnozoites. Despite the number of vivax cases and the number of relapses, there were only 28 recorded primaquine prescriptions (3.4% of vivax episodes, 4.5% of subjects).The present study points out that despite the fact that nearly half of the P. vivax cases, many of which in children, are caused by latent hypnozoites, only a minority of them benefit from primaquine radical cure. The obstacles to this are discussed and suggestions are made to reduce the burden of vivax malaria in Camopi and other remote health centres in French Guiana.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.